Credit: Shutterstock photoGainesville, FL-based Exactech Inc.EXAC recently announced the launch of a new software application christened ExactechGPS TKA PLUS. The application provides orthopaedic surgeons simplified, real-time intraoperative computer guidance during total knee arthroplasty (TKA).
Stock Performance
For the last three months, Exactech has been trading above the Zacks categorized Medical Instruments sub-industry. The company's stock gained 15.07%, higher than the sub-industry's paltry gain of 9.96%. We believe that the company is currently riding high on its regulatory approvals and product launches.
Coming back to the news, the ExactechGPS is a computer technology system for guided, personalized joint replacement surgery. The new TKA PLUS software application provides surgeons a simple tool to plan, guide and verify key steps of a knee replacement procedure and easily check the patient's implant alignment. This application expands the ExactechGPS knee software portfolio, which also includes comprehensive applications for primary and revision knee surgery. ExactechGPS has been used in more than 8,500 total knee cases in 12 countries across the globe.
Going forward, management is bullish over the expansion of the ExactechGPS Shoulder Application and is optimistic that it would continue to witness the current selling momentum. The application's global sales surged 21% in the first quarter of 2017 and has been used successfully in the U.K., Spain, France and Australia.
Exactech develops and markets orthopaedic implant devices, surgical instruments and biologic materials. The company's orthopaedic products are used in the restoration of bones and joints that have deteriorated due to injuries or diseases. Exactech markets its products in the US, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific.
Zacks Rank & Key Picks
Currently, Exactech has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Inogen Inc. INGN , Mesa Laboratories, Inc. MLAB and Edap Tms S.a. EDAP . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 100%.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four quarters. Notably, the stock represents an impressive one-year return of 16.7%.
Edap Tms represents a stellar one-year return of 2.2% for the last three months. The company provided a solid earnings surprise of 533.3% in the last reported quarter.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report
EDAP TMS S.A. (EDAP): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
Exactech, Inc. (EXAC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
